Clinical Trials Logo

Clinical Trial Summary

This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the clinical and quality of life outcomes between these diagnostic modalities in patients with suspected muscle-invasive bladder cancer (MIBC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06335667
Study type Interventional
Source University of California, Irvine
Contact Chao Family Comprehensive Cancer Center University of California
Phone 1-877-827-8839
Email ucstudy@uci.edu
Status Recruiting
Phase N/A
Start date March 27, 2024
Completion date April 2030

See also
  Status Clinical Trial Phase
Recruiting NCT04687254 - Gender-related Characteristics of Bladder Cancer Treatment
Recruiting NCT04099589 - Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma Phase 2
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Active, not recruiting NCT02462239 - Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging N/A
Recruiting NCT04660344 - A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy Phase 3
Withdrawn NCT03832673 - Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study Phase 2
Recruiting NCT06373055 - Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Terminated NCT03234153 - Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin Phase 2
Recruiting NCT05945108 - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting NCT06362330 - Multi-parametric MRI in Patients of Bladder Cancer
Completed NCT04209114 - A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Phase 3
Active, not recruiting NCT00808639 - Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Phase 2